<html>
<head>
	<META HTTP-EQUIV="Pragma" CONTENT="no-cache">
	<META HTTP-EQUIV="Cache-Control" CONTENT="no-store">
	<title> UK Government/ Prime Minister announces results of pharmaceutical  industry competitiveness task force jointly published with the  Association of <> </title>
<!-- Hiding from old browsers -->
<SCRIPT LANGUAGE=JavaScript>
   function userButton(btnStr)
   {
      document.forms[0].theButton.value = btnStr;
      document.forms[0].submit();
   }
<!-- End Hiding from old browsers -->
</SCRIPT>
</head>

<body BGCOLOR="#FFFFFF">
<table border="0" cellspacing="0" cellpadding="0" width="468">
<TR><TD width="468">
<FONT FACE="verdana, arial, helvetica, san-serif" SIZE="+1">

<!-- Begin DoubleClick ad head --><NOLAYER><IFRAME SRC="http://ad.doubleclick.net/adi/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=top;sz=468x60;tile=1;ord=985936558979?" name="banner1" frameborder=0 marginheight=0 marginwidth=0 width=468 height=80 scrolling=no><A HREF="http://ad.doubleclick.net/jump/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;abr=!ie;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=top;sz=468x60;tile=1;ord=985936558979?" target="_top"><IMG BORDER="0" SRC="http://ad.doubleclick.net/ad/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;abr=!ie;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=top;sz=468x60;tile=1;ord=985936558979?"><BR>Click Here!</A></IFRAME></NOLAYER><ILAYER ID=banner1 VISIBILITY=HIDE HEIGHT=80 WIDTH=468></ILAYER><!-- End DoubleClick ad head -->

<br>
<br>
<B>UK Government/ Prime Minister announces results of pharmaceutical  industry competitiveness task force jointly published with the  Association of <></B></FONT>
</td></tr>
<!--blue line -->
<TR>
<TD BGCOLOR="#003366"><IMG SRC="/images/util/dotclear.gif" HEIGHT="4" WIDTH="1"></TD>
</TR> 

<TR><TD width="468"> 
	<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" width="468">
    <TR>
	<!-- story area -->
    <TD VALIGN="top" width="468">
      <TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" width="328">
        <TR><TD width="328"><IMG SRC="/images/util/dotclear.gif" WIDTH="1" HEIGHT="5"></TD></TR>
		<TR><TD width="328"><FONT FACE= "verdana, arial, helvetica, san-serif">
		<FONT SIZE="-1"> <B> March 29, 2001
 </B><br><br><input type="Hidden" NAME="theButton"><A HREF=JavaScript:userButton("Email_frames")><img src="/images/buttons/email_story_to_a_friend_b.gif" border="0"></A>&nbsp;<A HREF=JavaScript:userButton("Fax_frames")><img src="/images/buttons/fax_story_to_a_friend_b.gif" border="0"></A><BR> <HR SIZE="1" NOSHADE><P>
		
<!-- begin full-text -->
<P></P>
<P>
The Prime Minister today launched publication of the final Report of  the Task
Force that has been looking at the competitiveness of the UK  based
pharmaceutical industry.
</P>
<P>
Launching the report in the company of Task Force's joint chairs Tom  McKillop,
CEO of AstraZeneca and Health Minister Lord Philip Hunt, the  Prime Minister
said: &quot;The UK pharmaceutical industry is one of our most  important and most
successful industries. Its products benefit people  here and round the world and
it makes a substantial contribution to our  economic welfare.
</P>
<P>
&quot;It is a truly global industry. Companies have a real choice about  where to
invest. The UK cannot rest on its laurels. We have to ensure  the UK remains an
attractive place for new investment. We set up the  Task Force to see what
needed to be done and to take action to maintain  and develop the UK's
competitive edge.&quot; Thanking Mr McKillop and Lord  Hunt for their work, the Prime
Minister added: &quot;The Task Force has done  an excellent job. It shows what can be
achieved when we work together  on issues - both between government and industry
and across  government.&quot; The report sets out action taken or in hand on a range
of  issues including : Industry and Government agreed on the essential role
that intellectual property rights (IPR) and the TRIPs agreement play,  and
should continue to play, in the flow of innovative medicines.
</P>
<P>
One of the most important outputs of the Task Force is the renewed
industry/Government partnership to work towards improving access to  medicines
in developing countries.
</P>
<P>
Streamlining licensing procedures for essential research involving  animals has
been agreed, cutting red tape and improving animal welfare.  This complements
amendments to the Criminal Justice and Police Bill and  Malicious Communications
Act to tackle harassment and intimidation by  animals rights campaigners.
</P>
<P>
A more forward looking strategic dialogue about developments in  healthcare and
the market for medicines in the UK. For example,  Government and industry are
engaged in comprehensive discussions about  how NICE operates, including its
impact uptake of new medicines, on the  competitiveness of the industry, and on
the economy more generally.  These discussions will inform a review of NICE,
including all  stakeholders, to be held in July.
</P>
<P>
Involving the industry closely in the development of NHS services -  such as
ensuring the NHS stays at the forefront of development of  modern treatments and
research, better use of the NHS database for  pharmaceutical research and
development, improving information to  patients, securing better patient
involvement in taking medicines and  ways of enabling people to secure better
access to those medicines not  available on the NHS.
</P>
<P>
Agreement that new policy measures should not be viewed in isolation,  but as
part of the overall environment. The impact of new policy  directions on UK
competitiveness ought to be considered with the  pharmaceutical industry prior
to implementation.
</P>
<P>
Industry and government agreed positions on a range of medicines policy  issues
under discussion in the European Union. The scope of these has  included aspects
of how the EU medicines licensing system might  develop, issues around EU
enlargement and some key matters of IPR  protection.
</P>
<P>
Indicators of performance and competitiveness have been agreed which  will
allow government and industry to measure and monitor the progress  of the UK as
a competitive location for pharmaceutical investment.
</P>
<P>
Tom McKillop said: &quot;The UK Government has demonstrated its willingness  to work
with us on ensuring the UK stays at the forefront of world  pharmaceutical
industry competitiveness. We have made significant  progress on many issues.
</P>
<P>
&quot;There is work still to be done on matters that affect the  competitiveness of
the industry but there is a commitment from all of  us to maintain the high
level of government/industry contact we have  enjoyed in the Task Force. This
experience has shown us how much is  possible when there is commitment and
goodwill on both sides.&quot; Lord  Hunt added: &quot;The Task Force has worked at the
centre of a unique  relationship between industry and government. We purchase
some GBP6  billion worth of pharmaceuticals for the NHS each year, we regulate
the  industry as part of a European licensing system for the safety, quality
and efficacy of its products and we support its significant  contribution to the
UK economy.
</P>
<P>
&quot;The Task Force has shown it is possible to reconcile these interests  in ways
that are mutually beneficial to the industry, to government, to  the NHS and its
patients and to the nation as a whole. We have produced  some important tangible
outputs as well as identifying areas where more  work needs to be done. One of
our most important achievements therefore  is agreement on a successful
mechanism to take forward the work and  spirit of PICTF. We in the UK will carry
that spirit forward too in  European discussions led by Commissioners Liikanen
and Byrne.&quot;
</P>
<P>
NOTES TO EDITORS:
</P>
<P>
1. The Pharmaceutical Industry Competitiveness Task Force (PICTF) was
</P>
<P>
set up by the Prime Minister in March 2000 for the Government and  industry to
work in partnership to see what action needs to be taken to  ensure the UK
remains an attractive place for the pharmaceutical  industry to locate its
business in an increasingly competitive global  environment.
</P>
<P>
2. European Commissioners Liikanen and Byrne have established a small  high-
level group to look at a number of pharmaceutical policy issues.  The Group met
for the first time on Monday March 26 in Brussels. Lord  Hunt is a member of the
group.
</P>
<P>
3. The Task Force members were: Co-chairmen: Lord Hunt of Kings Heath
(Parliamentary Under Secretary of State for Health) and Tom McKillop
(AstraZeneca) Lord Sainsbury of Turville (Minister for Science and  Innovation)
Baroness Blackstone (Minister of State for Education and  Employment) Nick
Raynsford MP (Minister for Housing and Planning)  Stephen Timms MP (Financial
Secretary) Nigel Crisp, Permanent  Secretary/Chief Executive DH Sir Richard
Sykes (Glaxo Wellcome) J-P  Garnier (SmithKline Beecham) Bill Fullager (ABPI
President and  Novartis) Vincent Lawton (APG Chairman and MSD) Trevor Jones
(ABPI  Director-General) 4. Copies of the final report are available on the
website http://www.doh.gov.uk/pictf.
</P>
<P>
5. For further information please call the Department of Health Media  Centre
on 020 7210 5230 or the Association of the British  Pharmaceutical Industry on
020 7747 1410.
</P>
<P>
((M2 Communications Ltd disclaims all liability for information  provided
within M2 PressWIRE. Data supplied by named party/parties.  Further information
on M2 PressWIRE can be obtained at  http://www.presswire.net on the world wide
web. Inquiries to  info@m2.com)).
</P>

<!-- end full-text -->

		<FORM METHOD="POST" ACTION="/servlet/EmailOrFax">
<INPUT TYPE="hidden" NAME="story" VALUE="m0328712.1to">
<INPUT TYPE="hidden" NAME="level1" VALUE="">
<INPUT TYPE="hidden" NAME="level2" VALUE="">
<INPUT TYPE="hidden" NAME="level3" VALUE="550">
<INPUT TYPE="hidden" NAME="date" VALUE="20010329">
<P>

<P>
<b>Would you like to email or fax this story<br>to a friend?</b></font><br><br></td>
	</tr>
	<tr>
		<td>&nbsp;&nbsp;&nbsp;&nbsp;
<!-- Buttons for Email and Fax a Friend -->

<input type="Hidden" NAME="theButton"><A HREF=JavaScript:userButton("Email_frames")><img src="/images/buttons/email_story_to_a_friend_b.gif" border="0"></A>&nbsp;<A HREF=JavaScript:userButton("Fax_frames")><img src="/images/buttons/fax_story_to_a_friend_b.gif" border="0"></A><br>
	</td>
</tr>
</table></TD>
	<!-- right hand column...(2) 120x90 ad, related stories, quicksearch, etc-->
	<TD ALIGN="right" VALIGN="top">
		<TABLE BGCOLOR="#FBEFD1" WIDTH="140" CELLPADDING="8" CELLSPACING="0" BORDER="0">
			<TR><TD BGCOLOR="#345B8A" HEIGHT="20"><FONT FACE="Verdana, Arial, Helvetica, sans-serif" COLOR="#FFFFFF" SIZE="-1"><B>More Articles</B></FONT></TD></TR>
<TR><TD><FONT FACE="Verdana, Arial, Helvetica, sans-serif" SIZE="-1"><A HREF="/frames/story.shtml?story=v0328152.9xi&date=20010329&level3=550">Int'l Symposium on Bio-Tech Medicine Held in Sh...</A></FONT></TD></TR>
<TR><TD><FONT FACE="Verdana, Arial, Helvetica, sans-serif" SIZE="-1"><A HREF="/frames/story.shtml?story=p0328084.901&date=20010329&level3=550">Schering-Plough Announces European Union Approv...</A></FONT></TD></TR>
<TR><TD><FONT FACE="Verdana, Arial, Helvetica, sans-serif" SIZE="-1"><A HREF="/frames/story.shtml?story=p0328112.900&date=20010329&level3=550">TKT's Replagal(TM) Receives Recommendation for ...</A></FONT></TD></TR>
<TR><TD><FONT FACE="Verdana, Arial, Helvetica, sans-serif" SIZE="-1"><A HREF="/frames/story.shtml?story=p0328131.500&date=20010329&level3=550">ICN Pharmaceuticals Says Schering-Plough Announ...</A></FONT></TD></TR>
<TR><TD><FONT FACE="Verdana, Arial, Helvetica, sans-serif" SIZE="-1"><A HREF="/frames/story.shtml?story=p0328081.902&date=20010329&level3=550">Schering AG Receives First Approval for Resovis...</A></FONT></TD></TR>
<TR><TD><FONT FACE="Verdana, Arial, Helvetica, sans-serif" SIZE="-1"><A HREF="/frames/story.shtml?story=m0328703.8to&date=20010329&level3=550">SMI/ New pharmaceutical management reports from...</A></FONT></TD></TR>

		<!-- Header topic_ad_tile 1-->	
			<TR><TD>
				<!-- Begin DoubleClick ad head --><NOLAYER><IFRAME SRC="http://ad.doubleclick.net/adi/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=button1;sz=120x90;tile=2;ord=985936558979?" name="tile1" frameborder=0 marginheight=0 marginwidth=0 width=120 height=90 scrolling=no><A HREF="http://ad.doubleclick.net/jump/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;abr=!ie;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=button1;sz=120x90;tile=2;ord=985936558979?" target="_top"><IMG BORDER="0" SRC="http://ad.doubleclick.net/ad/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;abr=!ie;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=button1;sz=120x90;tile=2;ord=985936558979?"></A></IFRAME></NOLAYER><ILAYER ID=tile1 VISIBILITY=HIDE HEIGHT=90 WIDTH=120></ILAYER><!-- End DoubleClick ad head -->

			</TD></TR>
	<!-- Header topic_ad_tile 2-->					
	<TR><TD>
				<!-- Begin DoubleClick ad head --><NOLAYER><IFRAME SRC="http://ad.doubleclick.net/adi/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=button2;sz=120x90;tile=3;ord=985936558979?" name="tile2" frameborder=0 marginheight=0 marginwidth=0 width=120 height=90 scrolling=no><A HREF="http://ad.doubleclick.net/jump/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;abr=!ie;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=button2;sz=120x90;tile=3;ord=985936558979?" target="_top"><IMG BORDER="0" SRC="http://ad.doubleclick.net/ad/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;abr=!ie;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=button2;sz=120x90;tile=3;ord=985936558979?"></A></IFRAME></NOLAYER><ILAYER ID=tile2 VISIBILITY=HIDE HEIGHT=90 WIDTH=120></ILAYER><!-- End DoubleClick ad head -->

			</TD></TR>

			 
			<TR>
      		<TD BGCOLOR="#345B8A" HEIGHT="20"><FONT FACE="verdana, arial, helvetica, san-serif" COLOR="#ffffff" SIZE="-1"><B>Quick Search</B></FONT></TD>
      		</TR>
      		<TR>
      		<TD ><FORM action="http://pf.individual.com/news_search.asp" METHOD=GET>
				<INPUT type="hidden" name="action" value="go">
				<INPUT type="hidden" name="start" value="1">
				<INPUT TYPE="TEXT" SIZE="13" VALUE="" NAME="text">
				<INPUT TYPE="Image" NAME="NewSearchSubmitBtn" SRC="/images/buttons/go_b.gif" alt="Submit" BORDER="0" WIDTH="22" HEIGHT="14" VSPACE="0" HSPACE="0">
				</FORM></TD>
      		</TR>
		</TABLE>
	</td>
	</tr>
</TABLE>

</td>
</tr>
		<tr><td><!-- Begin DoubleClick ad head --><NOLAYER><IFRAME SRC="http://ad.doubleclick.net/adi/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=bottom;sz=468x60;tile=4;ord=985936558979?" name="banner2" frameborder=0 marginheight=0 marginwidth=0 width=468 height=80 scrolling=no><A HREF="http://ad.doubleclick.net/jump/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;abr=!ie;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=bottom;sz=468x60;tile=4;ord=985936558979?" target="_top"><IMG BORDER="0" SRC="http://ad.doubleclick.net/ad/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;abr=!ie;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=bottom;sz=468x60;tile=4;ord=985936558979?"><BR>Click Here!</A></IFRAME></NOLAYER><ILAYER ID=banner2 VISIBILITY=HIDE HEIGHT=80 WIDTH=468></ILAYER><!-- End DoubleClick ad head -->
</td></tr>
	
<tr><td><br><IMG SRC="/images/logos/73x29.gif" WIDTH="73" HEIGHT="29"><FONT FACE="Verdana, Arial, Helvetica, sans-serif" SIZE="-2">&nbsp;&nbsp;<A HREF="/terms.shtml" TARGET="CONTENT"><B>Copyright &copy; 2001</B></A>, <A HREF="/about.shtml" TARGET="_top"><B>Individual.com, Inc.</A></B><font size="-5"><sup><font color="#0000CC">TM</font></sup></font>
</td></tr>
	
	</td>
</tr>
</table>

	
	<!-- Begin DoubleClick ad foot --><LAYER SRC="http://ad.doubleclick.net/adl/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=top;sz=468x60;tile=5;ord=985936558979?" visibility=hide onload="moveToAbsolute(banner1.pageX, banner1.pageY); clip.height=80; clip.width=468; visibility='show';"></LAYER><!-- End DoubleClick ad foot -->


	
	<!-- Begin DoubleClick ad foot --><LAYER SRC="http://ad.doubleclick.net/adl/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=button1;sz=120x90;tile=6;ord=985936558979?" visibility=hide onload="moveToAbsolute(tile1.pageX, tile1.pageY); clip.height=90; clip.width=120; visibility='show';"></LAYER><!-- End DoubleClick ad foot -->

					
		<!-- Begin DoubleClick ad foot --><LAYER SRC="http://ad.doubleclick.net/adl/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=button2;sz=120x90;tile=7;ord=985936558979?" visibility=hide onload="moveToAbsolute(tile2.pageX, tile2.pageY); clip.height=90; clip.width=120; visibility='show';"></LAYER><!-- End DoubleClick ad foot -->

			
	</SERVLET>
	<!-- Begin DoubleClick ad foot --><LAYER SRC="http://ad.doubleclick.net/adl/np.newspage.com/Pharmaceutical+Industry+-+Non+U.S.;depid=550;indid=46610;!category=np_comp;u=m0328712_1to;pos=bottom;sz=468x60;tile=8;ord=985936558979?" visibility=hide onload="moveToAbsolute(banner2.pageX, banner2.pageY); clip.height=80; clip.width=468; visibility='show';"></LAYER><!-- End DoubleClick ad foot -->



</body>
</html>
